Development of a mechanism of action-reflective, dual target cell-based reporter bioassay for a bispecific monoclonal antibody targeting human CTLA-4 and PD-1
T-cell-mediated immunotherapy has generated much excitement after the success of therapeutic biologics targeting immune checkpoint molecules. Bispecific antibodies (BsAbs) that recognize two antigen targets are a fast-growing class of biologics offering promising clinical benefits for cancer immunot...
Main Authors: | Weimin Chen, Madhu Pandey, Hong Sun, Andrea Rolong, Mingyan Cao, Dengfeng Liu, Jihong Wang, Lingmin Zeng, Alan Hunter, Shihua Lin |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2021-01-01
|
Series: | mAbs |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/19420862.2021.1914359 |
Similar Items
-
Simultaneous Inhibition of PD-1 and Stimulation of CD40 Signaling Pathways by Anti-PD-L1/CD40L Bispecific Fusion Protein Synergistically Activate Target and Effector Cells
by: Madhu S. Pandey, et al.
Published: (2021-10-01) -
Bioassay Development for Bispecific Antibodies—Challenges and Opportunities
by: Ames C. Register, et al.
Published: (2021-05-01) -
Targeted Selecting of Bioassay Methods as an Alternative to the “Battery of Bioassays”
by: Anna Olkova
Published: (2022-03-01) -
Comparative Characterization of Different Molecular Formats of Bispecific Antibodies Targeting EGFR and PD-L1
by: Nishant Mohan, et al.
Published: (2022-06-01) -
Development and Characterization of an In Vitro Cell-Based Assay to Predict Potency of mRNA–LNP-Based Vaccines
by: Nisarg Patel, et al.
Published: (2023-07-01)